Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials

International Archives of Allergy and Immunology

Volumn 156, Issue 1, 2011, Pages 1-15

  Compalati, E ^a   Baena Cagnani, R ^b,c   Penagos, M ^a   Badellino, H ^b,c   Braido, F ^a   Gomez R M ^c   Canonica, G W ^a   Baena Cagnani, C E ^a,b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b Chutro Clinic   (Argentina)

^c UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

Author keywords

Allergic rhinitis; Antihistamines; Evidence based medicine; Fexofenadine; Meta analysis

Indexed keywords

CETIRIZINE; DESLORATADINE; FEXOFENADINE; LORATADINE; PLACEBO;

ASTHENIA; ASTHMA; BACKACHE; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EPISTAXIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL PAIN; HAY FEVER; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; NASAL PRURITUS; NAUSEA; NOSE CONGESTION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINORRHEA; SEDATION; SENSITIVITY ANALYSIS; SIDE EFFECT; SINUSITIS; SNEEZING; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION;

ADULT; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME;

EID: 84860392559     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000321896     Document Type: Review

References (61)

1. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(suppl 5):S147-S334.
2. Bielory L: Ocular allergy overview. Immunol Allergy Clin North Am 2008; 28: 1-23.
3. Rosenwasser L: New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc 2007; 28: 10-15.
4. Demoly P, Allaert FA, Lecasble M, Bousquet J, PRAGMA: Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003; 58: 672-675.
5. Canonica GW, Bousquet J, Mullol J, Skadding GK, Virchow JC: A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62(suppl 85):17-25.
6. Storms W: Allergic rhinitis-induced nasal congestion: Its impact on sleep quality. Prim Care Respir J 2008; 17: 7-18.
7. Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, ISAAC Phase Three Study Group: Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009; 64: 123-148.
8. Bousquet J, van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J, et al: Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006; 61: 1086-1096.
9. Bousquet J, Bindslev-Jensen C, Canonica GW, Fokkens W, Kim H, Kowalsky M, et al: The ARIA/EAACI criteria for antihistamines: An assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59(suppl 77):S4-S16.
10. Walsh GM: Anti-inflammatory properties of antihistamines: An update. Clin Exp Allergy Rev 2005; 5: 21-25.
11. Nathan RA: The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis. Clin Ther 2008; 30: 573-586.
12. Kerryn S, Blair J: Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59: 301-321.
13. Van Cauwenberge P, Juniper EF, Star Study Investigating Group: Comparison of the efficacy, safety, and quality of life provided by fexofenadine 120 mg, loratadine 10 mg, and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891-899.
14. Howarth P, Stern M, Roi L, Reynolds R, Bousquet J: Double-blind, placebo controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-933.
15. Gross GN, Ganster K, Meeves S, Liao Y, Georges GC: A double-blind, randomized comparison of fexofenadine 180 mg versus cetirizine 10 mg: Effect on instantaneous symptom score at the 24th hour. Ann Allergy Asthma Immunol 2003; 90: 125.
16. Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G: Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354-361.
17. Tashiro M, Mochizuki H, Iwabuchi K, Sakurada Y, Itoh M, Watanabe T, et al: Roles of histamine in regulation of arousal and cognition: Functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002; 72: 409-414.
18. Mason J, Reynolds R, Rao N: The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999; 29(suppl 3):163-170.
19. Baena-Cagnani CE: Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004; 27: 883-898.
20. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ, GRADE Working Group: Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.
21. Shekelle PG, Woolf SH, Eccles M, Grimshaw J: Clinical guidelines: Developing guidelines. BMJ 1999; 318: 593-596.
22. Brozek JL, Baena-Cagnani CE, Bonini S, Canonica GW, Rasi G, van Wijk RG, Zuberbier T, Guyatt G, Bousquet J, Schünemann HJ: Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008; 63: 38-46.
23. Robinson KA, Dickersin K: Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31: 150-153.
24. The Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. 2008. http://www. cochrane-handbook.org.
25. Dawson B: Research questions about one group; in: Dawson B (ed): Basic and Clinical Biostatistics, ed 4. New York, McGraw-Hill, 2004, p 118.
26. Viera AJ, Garrett JM: Understanding interobserver agreement: The kappa statistic. Fam Med 2005; 37: 360-363.
27. DigitizeIt 1.5.7 program. Braunschweig, Bormann, 2003
28. Deeks JJ, Altman D, Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis; in Egger M, Davey Smith G, Altman DG, (eds): Systematic Reviews in Health Care. London, BMJ, 2001, pp 285- 312.
29. Egger M, Smith GD, Phillips AN: Meta-analysis: Principles and procedures. BMJ 1997; 315: 1533-1537.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
31. Sutton AJ, Higgins JP: Recent developments in meta-analysis. Stat Med 2008; 27: 625-650.
32. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Canonica GW: Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133: 599-609.
33. Analyses Version 5.0 for Windows. Oxford, The Cochrane Collaboration, 2008.
34. Berkowitz RB, Braker S, Lutz C, Jones P, Meeves S, Qiu C, Varghese ST, Georges G: Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96: 327-333.
35. Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Frankish CW, Chapman D, deGuia EC, Kramer B, Warner C: Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 h postdose, in the environmental exposure unit. Allergy Asthma Proc 2005; 26: 275-282.
36. Day JH, Briscoe MP, Rafeiro E, Hewlett D Jr, Chapman D, Kramer B: Randomized double- blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: Duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004; 25: 59-68.
37. Allocco FT, Votypka V, deTineo M, Naclerio RM, Baroody FM: Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol 2002; 89: 578-584.
38. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P: Levocetirizine has a longer duration of action on improving TNSS than fexofenadine after single administration. Br J Clin Pharmacol 2005; 60: 24-31.
39. Day JH, Briscoe MP, Welsh A, Smith JN, Clark A, Ellis AK, Mason J: Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533-540.
40. Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ: Comparative effects of desloratadine, fexofenadine and levocetirizine on nasal AD challenge in patients with perennial AR. Clin Exp Allergy 2004; 34: 650-653.
41. Berger WE, Lumry WR, Meltzer EO, Pearlman DS: Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006; 27: 214-223.
42. Hyo S, Fujieda S, Kawada R, Kitazawa S, Takenaka H: The efficacy of short-term administration of 3 antihistamines vs. placebo under natural exposure to Japanese cedar pollen. Ann Allergy Asthma Immunol 2005; 94: 457-464.
43. Meltzer EO, Casale TB, Nathan RA, Thompson AK: Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 311-317.
44. Lee DK, Gray RD, et al: A placebo controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 646.
45. Wilson AM, Haggart K, Sims EJ, Lipworth BJ: Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 1504-1509.
46. Wahn U, Meltzer EO, Finn AF Jr, Kowalski ML, Decosta P, Hedlin G, Scheinmann P, Bachert C, Rosado Pinto JE, Baena-Cagnani C, Potter P, Simons FE, Ruuth E: Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003; 111: 763-769.
47. Bronsky EA, Falliers CJ, Kaiser HB, et al: Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135-141.
48. Casale TB, Andrade C, Qu R: Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999; 20: 193-198.
49. Bernstein DI, Schoenwetter WF, Nathan RA, et al: Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443-448.
50. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J: Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-933.
51. Schapowal A, Study Group: Treating intermittent allergic rhinitis: A prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339. Phytother Res 2005; 19: 530-537.
52. Berger W, Lumry W, Meltzer O, et al: Efficacy of desloratadine 5 mg, compared to fexofenadine 180 mg in patients with symptomatic allergic rhinitis. Allergy Asthma Proc 2006; 27: 214-223.
53. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
54. Evidence-Based Medicine Working Group: Evidence-based medicine: A new approach to teaching the practice of medicine. JAMA 1992; 268: 2420-2425.
55. Bousquet J, Van Cauwenberge P: A critical appraisal of 'evidence-based medicine'in allergy and asthma. Allergy 2004; 59(suppl 78):12-20.
56. Sackett DL, Rosenberg WM, Gray JA, et al: Evidence-based medicine: What it is and what it isn't. BMJ 1996; 312: 71-72.
57. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
58. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ, GRADE Working Group: Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.
59. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. New Jersey, Lawrence Erlbaum, 1988.
60. Higgins J, Thompson S, Deeks J, Altman D: Statistical heterogeneity in systematic reviews of clinical trials: A critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7: 51-61.
61. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E: Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324